Coherus Oncology, Inc. (CHRS) key performance indicators and operating metrics (6 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| LOQTORZI Net Revenue | 11.8M | FY2026-Q1 |
| Net Loss Per Share from Continuing Operations (Diluted, Non-GAAP) | -0.25 USD_per_share | FY2026-Q1 |
| Non-GAAP Net Loss Per Share (Diluted) | -0.33 USD_per_share | FY2025-Q3 |
| Non-GAAP Net Loss from Continuing Operations | 39M | FY2025-Q2 |
| LOQTORZI Net Product Sales | 7.3M | FY2025-Q1 |
| UDENYCA Net Product Sales | 46.3M | FY2024-Q4 |
Back to CHRS overview · CHRS earnings · CHRS holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.